Transcript Practical I

Principles in Management of the Poisoned
Patient
 Toxicokinetics vs Toxicodynamics:
 The term "toxicokinetics" denotes the absorption, distribution, excretion, and
metabolism of toxins, toxic doses of therapeutic agents, and their metabolites.
 The term "toxicodynamics" is used to denote the injurious effects of these
substances on vital function.
 Volume of Distribution:
 The volume of distribution (Vd) is defined as the apparent volume into which a
substance is distributed
 Vd is increased by increased tissue binding, decreased plasma binding and
increased lipid solubility.
 Drug with high Vd extensive tissue distribution
 A large Vd implies that the drug is not readily accessible to measures aimed at
purifying the blood, such as hemodialysis.
 Examples of drugs with large Vd (> 5 L/kg) include antidepressants,
antipsychotics, antimalarials, narcotics, propranolol, and verapamil. Drugs
with relatively small volumes of distribution (< 1 L/kg) include salicylate,
phenobarbital, lithium, valproic acid, warfarin, and phenytoin
Antidotes, Definition and Types
 An antidote is a substance which can counteract a form of poisoning
 Types of Antidotes:
1. chemical antidotes combine with the poison to create a harmless compound.
For example, neutralization of acids by weak alkalis, e.g., (HCl  NaHCO3)
2. Physical antidotes prevent the absorption of the poison; e.g., activated
charcoal
3. Pharmacological antidotes counteract the effects of a poison by producing
the opposite pharmacological effects, e.g., ACHE inhibitors atropine
Some anatomic and neurotransmitter features of
autonomic and somatic motor nerves
N.B. Parasympathetic ganglia are not shown because most are in or near the wall of the organ innervated
Cholinergic
Transmission
After release from the presynaptic
terminal, ACh molecules may bind to and
activate an ACh receptor (cholinoceptor).
Eventually (and usually very rapidly), all of
the ACh released will diffuse within range of
an acetylcholinesterase (AChE) molecule.
AChE very efficiently splits ACh into
choline and acetate, neither of which has
significant transmitter effect, and thereby
terminates the action of the transmitter.
Most cholinergic synapses are richly
supplied with AChE; the half-life of ACh in
the synapse is therefore very short. AChE is
also found in other tissues, eg, red blood
cells.
Another cholinesterase with a lower
specificity for ACh, butyrylcholinesterase
[pseudocholinesterase], is found in blood
plasma, liver, glia, and many other tissues
Parasympathetic Nervous System,
Receptors for acetylcholine (cholinoceptors)
I.
Nicotinic receptors, nAChRs (the nicotinic actions of ACh are those that can
be reproduced by the injection of nicotine)
1.
At neuromuscular junctions of skeletal muscle (muscle type)





2.
Postsynaptic
Excitatory (increases Na+ permeability)
Agonists: ACh, carbachol (CCh), suxamethonium
Stimulate skeletal muscle (contraction)
Antagonists: tubocurarine, hexamethonium
On postganglionic neurons in the autonomic ganglia (ganglion type)





Postsynaptic
Excitatory (increases Na+ permeability)
Agonists: Ach, CCh, nicotine
Stimulate all autonomic ganglia
Antagonists: mecamylamine, trimetaphan
Parasympathetic Nervous System,
Nicotinic Receptors for acetylcholine
3.
On some central nervous system neurons (CNS type)





4.
Pre- and postsynaptic
Excitatory (increases Na+ permeability)
Agonists: nicotine, ACh
Pre- and postsynaptic stimulation of many brain regions
Antagonists: methylaconitine, mecamylamine
On adrenal medulla

Ach stimulates secretion of adrenaline from adrenal medulla
Parasympathetic Nervous System,
Muscarinic Receptors for acetylcholine
II.
Muscarinic receptors, mAChRs (the muscarinic actions of ACh are those
that can be reproduced by the injection of muscarine)
Location: mAChRs are located …

in tissues innervated by postganglionic parasympathetic neurons such as

On smooth muscle

On cardiac muscle

On gland cells

See next table for details.

in postganglionic sympathetic neurons to sweat glands

In the central nervous system
Muscarinic Autonomic Effects of Acetylcholine



















Eye (iris sphincter muscle)
Eye (ciliary muscle)
SA node
Atrium
AV node
Arteriole
Bronchial muscle
Bronchial secretion
GIT (motility)
GIT (secretion)
GIT (sphincters)
Gallbladder
Urinary bladder (detrusor)
Urinary bladder (trigone, sphincter)
Penis
Sweat glands
Salivary glands
Lacrimal glands
Nasopharyngeal glands
Contraction (miosis)
Contraction (for near vision)
Bradycardia
Reduced contractility
Reduced conduction velocity
Dilation (via nitric oxide)
Muscle Contraction
Increase
Increase
Increase
Relaxation
Contraction
Contraction
Relaxation
Erection (but not ejaculation)
Secretion (sympathetic cholinergic!)
Secretion
Secretion
Secretion
Parasympathetic Nervous System,
Summary of Intervention Mechanisms
 Cholinergic neurotransmission can
be modified at several sites,
including:
a) Precursor transport blockade, e.g.,
hemicholinium
b) Choline acetyltransferase inhibition,
……no clinical example
c) Promote transmitter release, e.g.,
choline, black widow spider venom
(latrotoxin)
d) Prevent transmitter release, e.g.,
botulinum toxin
e) Storage, e.g., vesamicol prevents ACh
storage
f) Cholinesterase inhibition, e.g.,
physostigmine, neostigmine
g) Receptors agonists (chlinomimetic
drugs) and antagonists (anticholinergic
drugs)
latrotoxin
+
Muscarinic Agonists (, Cholinomimetics,
Parasympathomimetics)

Acetylcholine itself is rarely used clinically because of its rapid hydrolysis following
oral ingestion and rapid metabolism following i.v. administration.

Fortunately, a number of congeners with resistance to hydrolysis (methacholine,
carbachol, and bethanechol) have become available.


Bethanechol is used (rarely) to treat gastroparesis, because it stimulates GI motility
and secretion, but at a cost of some cramping abdominal discomfort. In addition, it
may cause hypotension and bradycardia. Bethanechol is also widely used to treat
urinary retention. This agent also occasionally is used to stimulate salivary gland
secretion in patients with xerostomia (dry mouth, nasal passages, and throat)


There are also several other naturally occurring muscarinic agonists such as muscarine
and pilocarpine.
In rare cases, high doses of bethanechol have seemed to cause myocardial ischemia in
patients with a predisposition to coronary artery spasm
Pilocarpine is more commonly used than bethanechol to induce salivation, and also
for various purposes in ophthalmology. It is widely used to treat open-angle
glaucoma, topically. Pilocarpine possesses the expected side effect profile,
including increased sweating, asthma worsening, nausea, hypotension, and
bradycardia (slow heart rate).
Antichloinergic drugs
 Nonselective Muscarinic Antagonists
 The classical muscarinic antagonists are derived from plants and are nonselective
competitive antagonists. Atropa belladonna contains atropine. Hyoscyamus niger
contains primarily scopolamine and hyoscine.
 Clinically, atropine is used for raising heart rate during situations where vagal
activity is pronounced (for example, vasovagal syncope). It is also used for
dilating the pupils. Its most widespread current use is in pre-anesthetic
preparation of patients; in this situation, atropine reduces respiratory tract
secretions and thus facilitates intubation.
 Ipratropium (nonselective) is used by inhalation as a bronchodilator
 Cyclopentolate and tropicamide (both are nonselective also) are developed for
ophthalmic use and administered as eye drops
 Oxybutinin and tolterodine are new drugs developed for urinary incontinence
Antichloinergic drugs

•
•
•
•
•
•
•
•
•

Side effects of muscarinic antagonists include:
constipation,
xerostomia (dry mouth),
hypohidrosis (decreased sweating),
mydriasis (dilated pupils),
urinary retention,
precipitation of glaucoma,
decreased lacrimation,
tachycardia,
and decreased respiratory secretions
Selective Muscarinic Antagonists

Pirenzepine shows selectivity for the M1 muscarinic receptor.

Because of the importance of this receptor in mediating gastric acid release,
M1 antagonists such as pirenzepine help patients with ulcer disease or gastric
acid hypersecretion.
Cholinesterase Inhibitors
 The muscarinic and nicotinic agonists mimic acetylcholine effect by
stimulating the relevant receptors themselves.
 Another way of accomplishing the same thing is to reduce the destruction of
ACh following its release.
 This is achieved by cholinesterase inhibitors, which are also called the
anticholinesterases.
 They mimic the effect of combined muscarinic and nicotinic agonists.
 Cholinergic neurotransmission is especially important in insects, and it was
discovered many years ago that anticholinesterases could be effective
insecticides, by “overwhelming the cholinergic circuits” (see War Gases
below)
 By inhibiting acetylcholinesterase and pseudocholinesterase, these drugs
allow ACh to build up at its receptors. Thus, they result in enhancement of
both muscarinic and nicotinic agonist effect.
Cholinesterase Inhibitors, Reversible







"Reversible" cholinesterase inhibitors are generally short-acting. They bind AChE
reversibly. They include physostigmine that enters the CNS, and neostigmine and
edrophonium that do not.
Physostigmine enters the CNS and can cause restlessness, apprehension, and
hypertension in addition to the effects more typical of muscarinic and nicotinic agonists.
Neostigmine is a quaternary amine (tends to be charged) and enters the CNS poorly;
its effects are therefore almost exclusively those of muscarinic and nicotinic
stimulation. It is used to stimulate motor activity of the small intestine and colon, as in
certain types of non-obstructive paralytic ileus. It is useful in treating atony of the
detrusor muscle of the urinary bladder, in myasthenia gravis, and sometimes in
glaucoma.
Some patients encounter muscarinic side effects due to the inhibition of peripheral
cholinesterase by physostigmine.
The most common of these side effects are nausea, pallor, sweating and bradycardia.
Concomitant use of anticholinergic drugs which are quaternary amines (e.g.,
glycopyrrolate or methscopolamine and which therefore do not cross the blood-brain
barrier) are recommended to prevent the peripheral side effects of physostigmine.
Edrophonium (Tensilon®) is a quaternary amine widely used as a clinical test for
myasthenia gravis.

If this disorder is present, edrophonium will markedly increase strength. It often
causes some cramping, but this only lasts a few minutes.
Ambenonium and pyridostigmine are sometimes also used to treat myasthenia.
Cholinesterase Inhibitors, Irreversible






Long-acting or "irreversible" cholinesterase inhibitors (organophosphates) are
especially used as insecticides. Cholinesterase inhibitors enhance cholinergic
transmission at all cholinergic sites, both nicotinic and muscarinic. This makes
them useful as poisons.
They bind AChE irreversibly. Example: organophosphates (e.g.,
phosphorothionates)
Many phosphorothionates, including parathion and malathion undergo enzymatic
oxidation that can greatly enhance anticholinesterase activity. The reaction involves
the substitution of oxygen for sulphur. Thus, parathion is oxidized to the more
potent and more water-soluble paraoxon.
Differences in the hydrolytic and oxidative metabolism in different organisms
accounts for the remarkable selectivity of malathion.
In mammals, the hydrolytic process in the presence of carboxyesterase leads to
inactivation. This normally occurs quite rapidly, whereas oxidation leading to
activation is slow.
In insects, the opposite is usually the case, and those agents are very potent
insecticides.
Insecticide Poisoning

Causes and symptoms

Exposure to insecticides can occur by ingestion, inhalation, or exposure to skin
or eyes.
The chemicals are absorbed through the skin, lungs, and gastrointestinal tract
and then widely distributed in tissues.
Symptoms cover a broad spectrum and affect several organ systems:


•
•
•
•
•
•
•
Gastrointestinal: nausea, vomiting, cramps, excess salivation, and loss of bowel
movement control
Lungs: increases in bronchial mucous secretions, coughing, wheezing, difficulty
breathing, and water collection in the lungs (this can progress to breathing
cessation)
Skin: sweating
Eyes: blurred vision, smaller sized pupil, and increased tearing
Heart: slowed heart rate, block of the electrical conduction responsible of
heartbeat, and lowered blood pressure
Urinary system: urinary frequency and lack of control
Central nervous system: convulsions, confusion, paralysis, and coma